TOP TIERMARKET NEWSWIRE
Movers explained · 2026-11-17

Archived explainer. For the current picture see today's IDYA page.

Why Is IDEAYA BIOSCIENCES I (IDYA) Stock Down Today?

By the Top Tier Newswire AI Desk · November 17, 2026 at 11:39 AM ET · reviewed against 4 wire stories

IDEAYA BIOSCIENCES I (IDYA) is down -11.91% in the latest session. Our newswire has captured 4 stories on IDYA across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 58/100).

Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.

Ideaya Biosciences (IDYA) shares fell 11.91% to $26.75. The primary driver was the company’s announcement of a registrational trial strategy for IDE849, which outlines a path toward accelerated approval for neuroendocrine carcinomas.

What Happened

Ideaya reported a successful US FDA Type C meeting regarding Phase 2/3 registrational trial designs for IDE849, a DLL3-targeted antibody-drug conjugate. The company plans a single-arm extension cohort of approximately 90 refractory gastroenteropancreatic neuroendocrine carcinoma patients to support potential accelerated approval. The primary endpoint for this cohort is the confirmed objective response rate by blinded independent central review. Additionally, the company outlined plans for a randomized Phase 3 trial across multiple refractory neuroendocrine carcinoma subtypes to support full approval.

The stock also reacted to recent analyst activity. RBC Capital Markets lowered its price target on Ideaya to $45, while Wedbush adjusted its price target to $63 from $60. The company also nominated IDE101 as a development candidate for CDKN2A-deficient solid tumors.

What The Data Shows

Ideaya shares opened at $30.39 and hit a session high of $31.85 at 9:30 AM ET before sliding to a session low of $26.72 at 11:35 AM ET. Volume so far stands at 0.4 million shares, which is 0.5 times the 3-month daily average. The stock closed near its session low at $26.79.

Fundamentals indicate a market cap of $3.1 billion. The company is unprofitable with a trailing twelve-month EPS of -4.52 and revenue down 83.0% year-over-year. The 52-week range is $26.81 to $42.68. On November 17, 2026, the stock printed one fresh 52-week high and 25 fresh 52-week lows. CEO Yujiro Hata sold shares on October 6, 2026. Insider filings over the last 90 days show zero buys and one sale totaling $985,000.

What To Watch

Investors will monitor the execution of the IDE849 extension cohort and the subsequent randomized Phase 3 trial. The company is also scheduled to participate in upcoming November 2026 investor relations events.

AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.

IDYA by the numbers

Last: $26.75Session: -11.91%Coverage: 4 stories / 3 sourcesAI sentiment: 58/100 (bullish)Mkt cap: $3.1B52w: $26.81 to $42.68
IDYA · Nov 17 session (5-min) · -9.75% vs prior close · updated 8:46 PM ET
$26.54$28.58$30.61prev close $30.36$27.409:25 AM11:11 AM12:57 PM2:43 PM4:30 PM9:25 AM · $30.399:30 AM · $30.069:35 AM · $30.099:40 AM · $29.339:45 AM · $29.269:50 AM · $28.519:55 AM · $28.7010:00 AM · $28.4810:05 AM · $28.3310:10 AM · $27.9810:15 AM · $27.6910:20 AM · $27.7810:25 AM · $27.6910:30 AM · $28.0510:35 AM · $27.7310:40 AM · $27.5410:45 AM · $27.2510:50 AM · $26.9010:55 AM · $27.4011:00 AM · $27.5211:05 AM · $27.9311:10 AM · $28.0211:15 AM · $27.9811:20 AM · $27.4611:25 AM · $27.2311:30 AM · $26.8911:35 AM · $26.7911:40 AM · $26.7911:45 AM · $26.8911:50 AM · $26.8511:55 AM · $26.8312:00 PM · $26.7612:05 PM · $26.9912:10 PM · $26.9512:15 PM · $27.0912:20 PM · $26.9212:25 PM · $26.8612:30 PM · $26.8312:35 PM · $26.9812:40 PM · $27.0712:45 PM · $27.1512:50 PM · $27.4212:55 PM · $27.621:00 PM · $27.701:05 PM · $27.741:10 PM · $27.931:15 PM · $27.811:20 PM · $27.781:25 PM · $27.671:30 PM · $27.731:35 PM · $27.561:40 PM · $27.341:45 PM · $27.221:50 PM · $27.201:55 PM · $27.132:00 PM · $27.202:05 PM · $27.132:10 PM · $27.262:15 PM · $27.372:20 PM · $27.712:25 PM · $27.632:30 PM · $27.512:35 PM · $27.392:40 PM · $27.392:45 PM · $27.252:50 PM · $27.322:55 PM · $27.333:00 PM · $27.163:05 PM · $27.113:10 PM · $27.103:15 PM · $27.033:20 PM · $27.273:25 PM · $27.343:30 PM · $27.273:35 PM · $27.243:40 PM · $27.203:45 PM · $27.253:50 PM · $27.453:55 PM · $27.414:00 PM · $27.404:30 PM · $27.40
AI sentiment, last 36h · averaged over 4 stories · 58/100 bullish
AI sentiment 58/100 (bullish)0 · bearish50bullish · 100

The headlines behind the move

Story flow · 4 stories on the wire, last 36h · hover or tap a dot for the headline
36h ago24h ago12h agopublishSeeking Alpha · sentiment 53 · IDEAYA Biosciences, Inc. (IDYA) Presents at UBS Global Biopharma Conference 2026 TranscriptSeeking Alpha · 53IDEAYA Biosciences, Inc. (IDYA) Presents at UBS Global Biopharma Conference 2026 TranscriptPR Newswire · sentiment 64 · IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine CarcinomasPR Newswire · 64IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational…The Fly · sentiment 58 · Ideaya Biosciences reports on FDA Type C meeting on Phase 2/3 trial for IDE849The Fly · 58Ideaya Biosciences reports on FDA Type C meeting on Phase 2/3 trial for IDE849Seeking Alpha · sentiment 58 · Ideaya sets registrational trial strategy for IDE849 for neuroendocrine carcinomasSeeking Alpha · 58Ideaya sets registrational trial strategy for IDE849 for neuroendocrine carcinomas
3d agoSeeking AlphaBULLISH 58Product/PR

Ideaya sets registrational trial strategy for IDE849 for neuroendocrine carcinomas

Ideaya plans a 90-patient IDE849 extension cohort in GEP-NEC to support accelerated approval, with confirmed response rate as the primary endpoint. Read more here.

3d agoThe FlyBULLISH 58Product/PR

Ideaya Biosciences reports on FDA Type C meeting on Phase 2/3 trial for IDE849

3d agoPR NewswireBULLISH 64Product/PR

IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas

Single-arm extension cohort of approximately 90 refractory GEP-NEC patients to support potential accelerated approval, with ORR by BICR as the primary endpoint Randomized Phase 3 trial in multiple refractory NEC subtypes, including GEP-NEC and LC-NEC, is planned to support full approval,...

4d agoSeeking AlphaNEUTRAL 53Product/PR

IDEAYA Biosciences, Inc. (IDYA) Presents at UBS Global Biopharma Conference 2026 Transcript

IDEAYA Biosciences, Inc. (IDYA) UBS Global Biopharma Conference 2026 November 16, 2026 5:40 AM ESTCompany ParticipantsYujiro Hata - Founder, President, CEO...

Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →

More on IDYA: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.

Earlier IDYA move explainers: 2026-11-18 · 2026-11-17